Lantheus Holdings Inc logo

Lantheus Holdings Inc

LNTH
Healthcare|Drug Manufacturers - Specialty & Generic|USA
$105.64
-0.34 (-0.32%)
DCF (FCF)
$69.11
Tangible Book
$4.10
Graham Number
$22.41
Earnings Power
$25.99

About

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

Stock Price

+26.0%(1Y)

Pipeline Summary

86 total trials
26
Phase 1
21
Phase 2
12
Phase 3
10
Phase 4
Completed: 56NOT_YET_RECRUITING: 3Withdrawn: 5Active: 5Terminated: 4Unknown: 2ENROLLING_BY_INVITATION: 2Recruiting: 8TEMPORARILY_NOT_AVAILABLE: 1

Active Trials (13)

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
NCT03976843Prostate Cancer
Phase 2Active
Enrollment: 175 participants
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
NCT06074510Prostate Cancer
Phase 4Active
Enrollment: 274 participants
Prediction of ARrhythmic Events With Positron Emission Tomography II
NCT03493516Sudden Cardiac Arrest
Active
Enrollment: 302 participants
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
NCT07335315Pituitary Adenoma
Recruiting
Enrollment: 110 participants
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
NCT05394259Pancreatic Cancer
Phase 1Recruiting
Enrollment: 36 participants

BioScore

4.3/10
Cautious

Ownership

Recent Insider Trades

PATEL RAJIV ASELL
2025-08-203,406,000 shares @ $56.14
FARALLON PARTNERS L L C/CASELL
2025-08-203,406,000 shares @ $56.14
Blanchfield PaulSELL
2025-08-133,060 shares @ $53.57
Niedzwiecki DanielSELL
2025-06-136,000 shares @ $78.74
McHugh JulieSELL
2025-06-095,192 shares @ $81.62

Recent News

2026-07-09 14:42:16
2026-07-09 00:28:43
2026-07-06 23:23:48
2026-06-29 13:35:11
2026-06-26 22:56:05
Data last updated: Jul 12, 2026, 07:39 PM